Showing results (311-320 of 363) with videos related to
Sort By:
Pageof 37
BJU International|August 26, 2024
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancerJacob I Taylor, Ashish M Kamat, Michael A O'Donnell, et al.European Urology Focus|December 19, 2018
Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical OutcomesCharlotte S Voskuilen, Roland Seiler, Michael Rink, et al.European Urology|August 14, 2022
Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder CancerAlberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al.Genome Medicine|October 18, 2019
Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosisJoep J de Jong, Yang Liu, A Gordon Robertson, et al.JCO Precision Oncology|July 8, 2026
Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision OncologySophia C Kamran, Monica Borges, Jeff Michalski, et al.European Urology|May 22, 2025
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder CancerMarie-Pier St-Laurent, Parminder Singh, David J McConkey, et al.The American Journal of Surgical Pathology|September 17, 2019
Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder CarcinomaCharlotte S Voskuilen, Htoo Zarni Oo, Vera Genitsch, et al.European Urology Oncology|December 18, 2024
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder CancerJacob Taylor, Ashish M Kamat, Drupad Annapureddy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2023
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer GroupAshish M Kamat, Andrea B Apolo, Marek Babjuk, et al.European Urology Oncology|March 25, 2020
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific DifferencesJoep J de Jong, Joost L Boormans, Bas W G van Rhijn, et al.Pageof 37